Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Paying user area
Try for free
Medtronic PLC pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Medtronic PLC for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Historical Valuation Ratios (Summary)
Based on: 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
The financial ratios reveal several notable trends over the analyzed quarters.
- Price to Earnings (P/E) Ratio
- The P/E ratio exhibited significant fluctuations, reaching a peak in early 2021 at 55.13 before declining steadily to a low of approximately 22.61 in mid-2022. Following this decline, the ratio showed a moderate upward correction, generally stabilizing around the high 20s. This pattern suggests initial market optimism followed by tempered expectations, potentially reflecting earnings growth or changes in market valuation sentiment during this period.
- Price to Operating Profit (P/OP) Ratio
- The P/OP ratio mirrored the broader trend observed in the P/E ratio, with an initial high point near 49.88 in early 2021, followed by a sharp decline through 2022 to a trough near 17.99. Since then, a gradual recovery has been observed, with values climbing back to the low twenties. This trend may indicate improvements in operating profitability or adjustments in market pricing relative to operating profit.
- Price to Sales (P/S) Ratio
- The P/S ratio showed a more gradual decline over the time frame, starting above 5.0 and decreasing consistently to around 3.3–3.5 in recent periods, with a slight uptick noted towards the final quarters. This steady decline could suggest that the market's valuation relative to sales decreased, possibly due to higher revenue figures or shifts in market valuation multiples.
- Price to Book Value (P/BV) Ratio
- The P/BV ratio also experienced a downward trend initially, moving from just under 3.5 to around 2.0–2.2 by late 2022. More recently, the ratio trended modestly upward, reaching close to 2.8 in the latest quarter. This movement may reflect changes in the company's book value, market capitalization, or shifts in investor sentiment towards asset valuation.
Overall, the documented ratios indicate a period of peak valuation in early 2021, followed by a correction phase across multiple valuation metrics, with some degree of stabilization or recovery in the most recent quarters. These trends are consistent with a market environment that initially priced the company at optimistic levels before recalibrating expectations in light of operational results and broader economic conditions.
Price to Earnings (P/E)
| Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||||||
| Net income attributable to Medtronic (in millions) | |||||||||||||||||||||||||||||
| Earnings per share (EPS)2 | |||||||||||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||||||||||
| P/E ratio4 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| P/E Ratio, Competitors5 | |||||||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Data adjusted for splits and stock dividends.
2 Q2 2026 Calculation
EPS
= (Net income attributable to MedtronicQ2 2026
+ Net income attributable to MedtronicQ1 2026
+ Net income attributable to MedtronicQ4 2025
+ Net income attributable to MedtronicQ3 2025)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Medtronic PLC Quarterly or Annual Report.
4 Q2 2026 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =
5 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals distinct trends in share price, earnings per share (EPS), and the price-to-earnings (P/E) ratio over the period examined.
- Share Price
- The share price showed an overall volatile behavior. Initially, there was a rise from approximately $106.15 to a peak of $134.73 between July 2020 and July 2021. Subsequently, the price declined sharply to a low near $79.25 by October 2022. Following this trough, the share price fluctuated moderately with no clear directional trend, ending higher at $105.35 by October 2025. This pattern suggests periods of higher market optimism followed by correction phases and then stabilization towards the end of the period.
- Earnings per Share (EPS)
- The EPS exhibited a less volatile but cyclical pattern compared to the share price. Initially, EPS decreased from 3.28 in July 2020 to a low of 2.15 in January 2021, then climbed steadily to a peak of 3.92 by July 2022. After a brief decline, the EPS showed repeated oscillations but generally remained within a range of 2.7 to 3.7. The EPS reached its highest levels towards the end of the timeline, around 3.63 to 3.72, indicating improving profitability or earnings consistency over time.
- Price-to-Earnings (P/E) Ratio
- The P/E ratio demonstrated considerable fluctuation with a notable initial increase from about 32.34 in July 2020 to a high of approximately 55.13 in January 2021. From this peak, there was a sustained downtrend reaching a low near 22.61 by July 2022. Subsequently, the ratio oscillated between roughly 23 and 31 with a moderate tendency to increase towards the later dates, ending at 28.35 by October 2025. This shift reflects changes in market valuation relative to earnings, first exhibiting high investor expectations that moderated over time, followed by a somewhat more balanced valuation approach in later quarters.
In summary, the financial indicators reflect an initial period of rising share price and market optimism accompanied by fluctuating earnings. After mid-2021, the share price declined sharply, while EPS continued a moderate upward trend with some volatility. The P/E ratio also peaked early and then declined, suggesting reduced market enthusiasm relative to earnings before stabilizing. Toward the end of the analyzed period, earnings improved steadily, and market valuation measured by P/E ratio moved towards more moderate levels while share price showed signs of recovery, pointing to a possible stabilization phase with improved earnings performance.
Price to Operating Profit (P/OP)
| Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||||||
| Operating profit (in millions) | |||||||||||||||||||||||||||||
| Operating profit per share2 | |||||||||||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||||||||||
| P/OP ratio4 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| P/OP Ratio, Competitors5 | |||||||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Data adjusted for splits and stock dividends.
2 Q2 2026 Calculation
Operating profit per share
= (Operating profitQ2 2026
+ Operating profitQ1 2026
+ Operating profitQ4 2025
+ Operating profitQ3 2025)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Medtronic PLC Quarterly or Annual Report.
4 Q2 2026 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =
5 Click competitor name to see calculations.
The share price demonstrated notable fluctuations throughout the observed periods. Initially, the price increased from approximately 106 US$ to a peak of around 135 US$ by mid-2021. A subsequent pronounced decline followed, reaching a low near 79 US$ in late 2022. After this low point, the share price showed variability with moderate recovery, oscillating between approximately 79 US$ and 105 US$ towards the end of the timeline, ending on an upward trajectory.
Operating profit per share exhibited a generally consistent upward trend. Starting near 3 US$, it rose steadily, reaching above 4 US$ by late 2021. From that point onward, operating profit per share maintained a relatively stable level, with slight fluctuations around the 4 to 4.85 US$ range. The upward movement indicates improving profitability on a per-share basis over the long term.
The price-to-operating-profit (P/OP) ratio showed considerable variation, reflecting the interplay between share price and operating profit per share. Initially high in the 30s and near 50, the ratio sharply declined during periods when share prices fell or operating profit increased, reaching a low near 18 in late 2022. Following this, the ratio experienced moderate increases and decreases, typically ranging between about 19 and 22 in the later periods. This suggests that market valuations relative to operating profit became more conservative after the earlier peak, with some stabilization in valuation multiples over recent periods.
- Summary of trends:
- - The share price experienced an early rise followed by a significant downturn and later partial recovery with volatility.
- - Operating profit per share steadily increased over time, indicating improved operational profitability.
- - The P/OP ratio decreased substantially from initial high levels, then stabilized within a narrower range, reflecting changing investor sentiment or market conditions relative to profit growth.
Overall, the financial data reveals a scenario where profit growth was relatively consistent, while market valuation showed greater sensitivity to external or company-specific factors, leading to fluctuations in share price and valuation multiples. The stabilization of operating profit per share with moderate P/OP ratios in recent periods may indicate a maturing valuation environment following prior volatility.
Price to Sales (P/S)
| Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||||||
| Net sales (in millions) | |||||||||||||||||||||||||||||
| Sales per share2 | |||||||||||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||||||||||
| P/S ratio4 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| P/S Ratio, Competitors5 | |||||||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Data adjusted for splits and stock dividends.
2 Q2 2026 Calculation
Sales per share
= (Net salesQ2 2026
+ Net salesQ1 2026
+ Net salesQ4 2025
+ Net salesQ3 2025)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Medtronic PLC Quarterly or Annual Report.
4 Q2 2026 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =
5 Click competitor name to see calculations.
The analysis of key financial metrics over the specified periods reveals distinct trends in share price, sales per share, and the price-to-sales (P/S) ratio.
- Share Price
- The share price exhibited an initial upward trajectory, rising from approximately $106.15 to a peak near $134.73 within the first year, indicating strong market sentiment. However, this was followed by a significant decline to a low around $79.25 over the subsequent year. In more recent periods, the share price showed some recovery, climbing back to over $105.35 by the final reported date. This cyclical pattern suggests fluctuations in market valuation possibly driven by external factors influencing investor confidence.
- Sales per Share
- Sales per share demonstrated a steady and gradual increase throughout the entire time frame. Starting at just above $20.78, sales per share rose consistently to approximately $27.11 by the end of the period. This trend indicates a stable growth in revenue generation on a per-share basis, reflecting either increased sales volume, prices, or efficient revenue management without notable volatility.
- Price-to-Sales (P/S) Ratio
- The P/S ratio mirrored the share price trend to some extent but showed more volatility. Initially high at 5.11, it climbed slightly before dropping sharply to below 3.5 in later periods, reflecting the share price decline relative to sales per share. Following the trough, the P/S ratio partially recovered to just under 3.9. This movement implies that the share price's fluctuations were more pronounced compared to sales growth, likely indicating changes in market valuation relative to the company’s sales performance.
Overall, the steady rise in sales per share suggests robust operational performance. In contrast, the pronounced fluctuations in share price and P/S ratio reflect varying market perceptions and potential external influences affecting stock valuation. The divergence between stable sales growth and more volatile share price performance warrants attention to underlying factors such as broader market conditions, industry trends, or company-specific developments impacting investor sentiment.
Price to Book Value (P/BV)
| Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||||||
| Shareholders’ equity (in millions) | |||||||||||||||||||||||||||||
| Book value per share (BVPS)2 | |||||||||||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||||||||||
| P/BV ratio4 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| P/BV Ratio, Competitors5 | |||||||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Data adjusted for splits and stock dividends.
2 Q2 2026 Calculation
BVPS = Shareholders’ equity ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Medtronic PLC Quarterly or Annual Report.
4 Q2 2026 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =
5 Click competitor name to see calculations.
The share price demonstrated a notable increase from July 2020 to July 2021, rising from approximately $106 to $135. This was followed by a considerable decline starting in October 2021, with the price falling to a low near $79 by October 2022. Subsequent quarters showed moderate recovery and fluctuation, with the share price gradually climbing again to above $105 by October 2025.
In contrast, the book value per share (BVPS) displayed relative stability over the entire period. It fluctuated within a narrow range, starting around $37.4 in mid-2020, peaking slightly above $39.6 in mid-2022, and then returning near $37.9 by late 2025. There was no significant upward or downward trend in the book value per share, indicating consistent underlying equity value per share without major changes in the company's net asset base.
The price-to-book value (P/BV) ratio illustrated the combined implications of the share price movement relative to the book value trends. Initially, the ratio increased from about 2.84 to 3.52 during the first year, reflecting investor optimism or valuation expansion beyond the book value. Subsequently, the P/BV ratio declined sharply to around 2.03 by late 2022, mirroring the share price decrease and suggesting a lower market valuation relative to book value. Following this low, the P/BV ratio showed some recovery and oscillation, ending near 2.78 in the final quarter, consistent with the partial rebound in share price.
- Share Price Trends
- Strong growth during the first year, followed by a significant decline and then a gradual recovery over the subsequent three years.
- Book Value Per Share Stability
- Relatively stable with minor fluctuations, indicating consistent net asset value.
- P/BV Ratio Dynamics
- Initial increase reflecting growing market valuation, a marked correction aligning with share price drop, and a partial rebound toward the end.
Overall, the data suggests a period of market optimism and expansion followed by adjustment reflecting either market conditions or company-specific factors affecting share price, while fundamental equity value remained largely steady. The fluctuations in valuation multiples point to changing investor sentiment and assessment of the company's growth prospects or risk profile over time.